Dr. Reddy's Laboratories Limited (RDY)
| Market Cap | 13.16B |
| Revenue (ttm) | 3.58B |
| Net Income (ttm) | 636.55M |
| Shares Out | 833.05M |
| EPS (ttm) | 0.76 |
| PE Ratio | 20.68 |
| Forward PE | 18.89 |
| Dividend | $0.57 (3.74%) |
| Ex-Dividend Date | Jul 30, 2024 |
| Volume | 1,559,189 |
| Open | 15.46 |
| Previous Close | 15.12 |
| Day's Range | 15.35 - 15.55 |
| 52-Week Range | 13.41 - 16.89 |
| Beta | 0.33 |
| Analysts | Buy |
| Price Target | 17.00 (+10.61%) |
| Earnings Date | Jan 28, 2025 |
About RDY
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI se... [Read more]
Financial Performance
In 2023, Dr. Reddy's Laboratories's revenue was 279.16 billion, an increase of 13.54% compared to the previous year's 245.88 billion. Earnings were 55.68 billion, an increase of 23.56%.
Financial numbers in INR Financial StatementsAnalyst Forecast
According to one analyst, the rating for RDY stock is "Buy" and the 12-month stock price forecast is $17.0.
News
Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. announced the launch of Toripalimab in India.
Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DrReddys--Dr. Reddy's Laboratories, Inc. and Senores Pharmaceuticals, Inc. today announced the launch of Ivermectin Tablets USP, 3 mg in the U.S. market.
Dr. Reddy's Laboratories Limited (RDY) Q2 2025 Earnings Call Transcript
Dr. Reddy's Laboratories Limited (NYSE:RDY) Q2 2025 Earnings Conference Call November 5, 2024 9:00 AM ET Company Participants Richa Periwal - Head of Investor Relations MV Narasimham - Chief Financia...
Dr. Reddy's Q2 & H1FY25 Financial Results
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DrReddys--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter and half year ended September 30, 2024.
Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #AmericanAssociationfortheAdvancementofScience--Dr. Reddy's has been ranked among the top employers according to the 2024 Top Biotech and Pharma Employers Su...
Dr. Reddy's Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month
PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's launches comprehensive menopause support program and training for employees during menopause awareness month.
Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India's First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma
BENGALURU, India & HYDERABAD, India--(BUSINESS WIRE)-- #AurigeneOncology--Aurigene Oncology announces promising results of Phase 1 study for India's first trial for novel autologous CAR-T cell therapy...
Dr. Reddy's signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries.
Dr. Reddy's Laboratories, Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial Drug
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #AurigenePharmaceutical--Dr. Reddy's Laboratories, Aurigene, and Kainomyx announce potential partnership for joint development of affordable anti-malarial dr...
Dr. Reddy's Laboratories: Economic Factors Square Off To Reiterate Buy
Dr. Reddy's Laboratories stock has risen 29% since my last publication, with additional tailwinds from legislative changes and strong business momentum. The company's enduring competitive advantage as...
Dr. Reddy's Laboratories: India 'will be our number one market'
Erez Israeli of Dr. Reddy's Laboratories says the company is "absolutely planning to play" in the biologics space, and while the U.S. remains a key market for the company, India and other markets will...
Dr. Reddy's Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #CHMP--Dr. Reddy's receives positive CHMP opinion from European Medicines Agency for its proposed Rituximab biosimilar.
Dr. Reddy's Q1FY25 Financial Results
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter ended June 30, 2024.
Dr. Reddy's to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #Acquisition--Dr. Reddy's to acquire Nicotinell and related portfolio in significant step towards building global consumer healthcare business.
Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities
HYDERABAD, India--(BUSINESS WIRE)-- #Aurigene--Aurigene inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India.
Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #CEO--Dr. Reddy's Laboratories Ltd. today announced the appointment of Milan Kalawadia as Chief Executive Officer, North America.
Alvotech and Dr. Reddy's Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
HYDERABAD, India & REYKJAVIK, Iceland--(BUSINESS WIRE)---- $RDY #Alvotech--Alvotech and Dr. Reddy's enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Proli...
Dr. Reddy's Laboratories Limited (RDY) Q4 2024 Earnings Call Transcript
Dr. Reddy's Laboratories Limited (NYSE:RDY) Q4 2024 Earnings Conference Call May 7, 2024 10:00 AM ET Company Participants Richa Periwal - Head of Investor Relations GV Prasad - Co-Chairman and Managi...
Dr. Reddy's Q4 & Full Year FY24 Financial Results
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2024.
Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #Capsules--Dr. Reddy's Laboratories announces the launch of Doxycycline Capsules, 40 mg* in the U.S. market.
Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #Avastin--Dr. Reddy's Laboratories Ltd., a global pharmaceutical company, announced the launch of Versavo® (bevacizumab) in the United Kingdom (UK).
Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal
Coya Therapeutics has strengthened its strategic positioning with a licensing deal with Dr. Reddy's, providing significant financial derisking and expanding its pipeline. The company has proven its ab...
Dr. Reddy's Q3 & 9M FY24 Financial Results
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #9MFY24--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter and nine months ended December 31, 2023.
Dr Reddy's Laboratories Ltd (RDY) Q3 2024 Earnings Call Transcript
Dr Reddy's Laboratories Ltd (RDY) Q3 2024 Earnings Call Transcript
Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women's Health and Dietary Supplements Portfolio of Brands
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #AmyrisInc--Dr. Reddy's announces the acquisition of MenoLabs®, a leading women's health and dietary supplements portfolio of brands.